Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: ahk-cu
Validated Laboratory Standard
Preclinical & Clinical Literature MonographSingle Peptide
AHK-Cu
Revision 1 · Lyophilized Solid Powder
Ala-His-Lys-Cu(II) Complex · Dermal Papilla & Hair Follicle Standard. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
AHK-Cu
Ala-His-Lys-Cu(II) Complex · Dermal Papilla & Hair Follicle Standard. Formulated for in-vitro research and laboratory analytical validation.
≥99.0% (HPLC-grade)Skin, Hair & Cellular Matrix
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)Localized dermal retention (~24 Hours)Typical protocol duration: 12 to 24 Weeks; Washout: 4 Weeks between research cohorts
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationWhat it is: AHK-Cu is a synthetic copper complex pairing the tripeptide L-alanyl-L-histidyl-L-lysine with copper(II), structurally distinct from GHK-Cu and specifically optimized for dermal papilla cell stimulation.
How it works: AHK-Cu upregulates Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) in dermal papilla cells while suppressing TGF-beta-induced follicle miniaturization, stimulating hair follicle elongation and dermal capillary density.
Why researchers study it: Researched as a targeted cosmetic and analytical agent in androgenetic alopecia, hair density enhancement, and scalp microcirculation.
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
Hair Follicle-Targeted Copper Tripeptide: Specifically engineered tripeptide with high affinity for dermal papilla cells.
✓
Stimulation of VEGF & Follicular Angiogenesis: Enhances capillary blood supply feeding hair follicle roots.
✓
Prolongation of Anagen Growth Phase: Suppresses apoptotic signals (TGF-beta1) that trigger premature follicle catagen transition.
✓
Dermal Extracellular Matrix Collagen Synthesis: Upregulates collagen type I and elastin in the scalp dermal sheath.
Physicochemical Specifications & Analytical Verification
≥99.0% (HPLC-grade)Primary Sequence / Chemical Formula
Ala-His-Lys:Cu2+ (AHK-Cu)
Diluent Ratio
5 mL per 50 mg (10 mg/mL)
Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
Lyophilized Storage
-20°C in dry desiccated container (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
Localized dermal retention (~24 Hours)
Typical protocol duration: 12 to 24 Weeks; Washout: 4 Weeks between research cohorts
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (50 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake50 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent2.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution25.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 250.0 mcg (0.01 mL)| Standard Compound Mass | 50 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 25.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 250.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— AHK-Cu
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)
1. Compound Mass50 mg
mg
Vials:
2. Diluent Volume5.0 mL
mL
Quick:
3. Target Assay Dose50.0 Units
Dissolution Vial
50mg / 5mL
Syringe: 100 U (1.0 mL Workhorse)
50.0 Units (0.500 mL)
0 U100 U
Selected Dose
5 mg
5000 µg active mass
Injection Volume
0.500 mL
500 µL draw
U-100 Syringe Mark
50.0 Units
Barrel Graduation
Single Vial Yield
~10.0 Doses
10 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: AHK-Cu•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (50mg / 5.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Weeks 1–2) | 2.5 mg | 25.0 Units(0.25 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 3–12) | 5 mg | 50.0 Units(0.50 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 13+) | 10 mg | 100.0 Units(1.00 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 50mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 55.0 mg
Active Vials (50mg):2 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 175.0 mg
Active Vials (50mg):4 vials
Sterile Syringes:24 U-100
BAC Water (10mL):2 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 50.0 Units (0.50 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 2.5 mg Topical | 0.25 mL | 25 Units 25.0 units (0.25 mL) on U-100 syringe |
| 5.0 mg Topical | 0.50 mL | 50 Units 50.0 units (0.50 mL) on U-100 syringe |
| 10.0 mg Topical | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
1.0 mL Precision Syringe
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent transfer
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle: 31G Ultra-Fine (0.25 mm)
Active Compound Mass50 mgSingle Lyophilized Vial
Diluent Volume Added5.0 mLBacteriostatic Water USP
Resulting Concentration10.00 mg/mLHomogenized Solution
Vial Yield~10.0 DosesPer Single Reconstituted Vial
Target Analytical Dose5 mg5000 µg active mass
Volumetric Draw0.500 mL (500 µL)Calibrated Liquid Draw
U-100 Syringe Graduation50.0 UnitsPlunger Barrel Mark
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 50.0 units (0.50 mL)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 2.5 mg Topical | 0.1 mL (100 µL) | 10 Units | 25.0 units (0.25 mL) on U-100 syringe |
| 5.0 mg Topical | 0.2 mL (200 µL) | 20 Units | 50.0 units (0.50 mL) on U-100 syringe |
| 10.0 mg Topical | 0.4 mL (400 µL) | 40 Units | 100.0 units (1.00 mL) on U-100 syringe |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
25 U-100 Units (0.25 mL)
Mass @ 25.0 mg/mL:6.25 mg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard
✓ Exact Tick Mark Alignment (25 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 83.3% of barrel
Tick Increment
0.5 Unit (5 µL)
Volumetric step
Low-Dead-Space (LDS)
<0.4 µL (0.16%)
Integrated needle waste
Measurement Error
±1.5%
ISO 8537 tolerance
Needle Configuration
31G (0.26mm)
5/16" (8mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (AHK-Cu)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 0.4 µL
Wastage per Titration:0.16% of dose
84-Day Cumulative Loss:0.84 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:18% of dose
84-Day Cumulative Loss:115.5 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 25 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 25 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 25 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 25 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for AHK-Cu.
Active Compound
385.00 mg
Across 12 weeks (84 doses)
Vials Required
9 × 50mg
Includes 8% dead-space buffer
Bacteriostatic Water
2 × 10 mL Bottles
18.0 mL total diluent
Sterile Syringes
97 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
194 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 9 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Stage 1: Dermal Calibration (Weeks 1–2) | 2.5 mg(7x/wk) | 10 Units(0.10 mL) | Vial #1(32.5mg rem) | 17.5 mg / 385.0 mg |
| Week 2 | Stage 1: Dermal Calibration (Weeks 1–2) | 2.5 mg(7x/wk) | 10 Units(0.10 mL) | Vial #1(15mg rem) | 35.0 mg / 385.0 mg |
| Week 3 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #2(15mg rem) | 70.0 mg / 385.0 mg |
| Week 4 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #3(15mg rem) | 105.0 mg / 385.0 mg |
| Week 5 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #4(15mg rem) | 140.0 mg / 385.0 mg |
| Week 6 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #5(15mg rem) | 175.0 mg / 385.0 mg |
| Week 7 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #6(15mg rem) | 210.0 mg / 385.0 mg |
| Week 8 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #7(15mg rem) | 245.0 mg / 385.0 mg |
| Week 9 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #8(15mg rem) | 280.0 mg / 385.0 mg |
| Week 10 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #9(15mg rem) | 315.0 mg / 385.0 mg |
| Week 11 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #10(15mg rem) | 350.0 mg / 385.0 mg |
| Week 12 | Stage 2: Follicle Activation (Weeks 3–12) | 5.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #11(15mg rem) | 385.0 mg / 385.0 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: 12 to 24 Weeks · Washout: 4 Weeks between research cohorts
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–2Starting Baseline | 2.5 mg | 1x Daily | Stage 1: Dermal Calibration: Scalp tolerance & capillary priming (0.25 mL solution at 10.0 mg/mL) |
| Weeks 3–12 | 5 mg | 1x Daily | Stage 2: Follicle Activation: VEGF and bFGF transcription (0.50 mL solution) |
| Weeks 13+ | 10 mg | 1x Daily | Stage 3: Hair Matrix Sustained: Anagen phase prolongation (1.00 mL solution) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓Hair Follicle-Targeted Copper Tripeptide: Specifically engineered tripeptide with high affinity for dermal papilla cells.
✓Stimulation of VEGF & Follicular Angiogenesis: Enhances capillary blood supply feeding hair follicle roots.
✓Prolongation of Anagen Growth Phase: Suppresses apoptotic signals (TGF-beta1) that trigger premature follicle catagen transition.
✓Dermal Extracellular Matrix Collagen Synthesis: Upregulates collagen type I and elastin in the scalp dermal sheath.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes!Topical or Mesotherapy Delivery: Investigated primarily via scalp topical solution or micro-needling carrier.
!Vibrant Blue Solution: Natural deep cobalt-blue color characteristic of chelated Cu(2+) ions.
!Store Away From Direct Sunlight: Photodegradation can dissociate copper coordination complex.
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
-20°C in dry desiccated container (24 months)
Reconstituted Solution
2°C–8°C refrigerated; use within 28 days
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for AHK-Cu
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at -20°C in dry desiccated container (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (1 References)
Peer-Reviewed IndexPMID: 17578401
Verified scientific reference.
Frequently Asked Questions
How should AHK-Cu (Copper Tripeptide-3) be reconstituted?
Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
What is the estimated laboratory half-life of AHK-Cu (Copper Tripeptide-3)?
AHK-Cu (Copper Tripeptide-3) displays an estimated half-life of Localized dermal retention (~24 Hours). Typical study protocols run for 12 to 24 Weeks followed by a washout period of 4 Weeks between research cohorts.
Pharmacological Profile and Mechanism
What it is: AHK-Cu is a synthetic copper complex pairing the tripeptide L-alanyl-L-histidyl-L-lysine with copper(II), structurally distinct from GHK-Cu and specifically optimized for dermal papilla cell stimulation.
How it works: AHK-Cu upregulates Vascular Endothelial Growth Factor (VEGF) and basic Fibroblast Growth Factor (bFGF) in dermal papilla cells while suppressing TGF-beta-induced follicle miniaturization, stimulating hair follicle elongation and dermal capillary density.
Why researchers study it: Researched as a targeted cosmetic and analytical agent in androgenetic alopecia, hair density enhancement, and scalp microcirculation.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 5 mL of Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Direct diluent stream gently against inner glass vial wall. Swirl in slow circular motions. Do not shake.
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear, colorless aqueous solution. Inspect against dark backdrop for optical clarity.
Storage and Temperature Stability
Lyophilized powder: -20°C in dry desiccated container (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 28 days. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 126928-65-2
PubChem CID: 135409405
Formula/Sequence: Ala-His-Lys:Cu2+ (AHK-Cu)
Molecular Weight: 416.94 g/mol
In-Vitro Concentration & Assay Schedule
• Stage 1: Dermal Calibration (Weeks 1–2): Target Assay Dose: 2.5 mg Topical | Cadence: 1x Daily
Assay Focus: Scalp tolerance & capillary priming
Volumetric Calibration: 0.25 mL solution at 10.0 mg/mL
• Stage 2: Follicle Activation (Weeks 3–12): Target Assay Dose: 5.0 mg Topical | Cadence: 1x Daily
Assay Focus: VEGF and bFGF transcription
Volumetric Calibration: 0.50 mL solution
• Stage 3: Hair Matrix Sustained (Weeks 13+): Target Assay Dose: 10.0 mg Topical | Cadence: 1x Daily
Assay Focus: Anagen phase prolongation
Volumetric Calibration: 1.00 mL solution
Typical Study Duration: 12 to 24 Weeks
Receptor Washout Window: 4 Weeks between research cohorts
All materials are synthesized strictly for controlled in-vitro and laboratory research use only. Not for human, veterinary, therapeutic, or clinical administration.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
AHK-Cu
Standard Lyophilized Monograph
Doc ID: PSL-SOP-AHKCU-REV1Rev: 1Category: Skin, Hair & Cellular MatrixDate: September 28, 2026
QR CODE
Verify Lot COApepstacklabs.com/sitemap.xml/research-protocols/ahk-cuPharmacological Profile & Monograph
Ala-His-Lys-Cu(II) Complex · Dermal Papilla & Hair Follicle Standard. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:AHK-Cu
CAS Registry Number:126928-65-2
PubChem CID:135409405
Molecular Weight:416.94 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:Ala-His-Lys:Cu2+ (AHK-Cu)
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · AHK-CUDOC ID: PSL-SOP-AHKCU-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 50 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 5.0 mL | 10.00 mg/mL | 1 Unit = 100.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (30 U / 0.3 mL)Target Mark: 25.0 Units (0.250 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 25.0 Units (0.250 mL)30 U (0.3 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 5.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · AHK-CUDOC ID: PSL-SOP-AHKCU-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 2.5 mg | 25.0 Units (0.250 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 3.8 mg | 37.5 Units (0.375 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 2.5 mg | 25.0 Units (0.250 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 50mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-AHKCU-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3